Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis.

@article{Chu2008RiskOH,
  title={Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis.},
  author={David Chu and Mario E. Lacouture and Triantafillos Fillos and Shenhong L Wu},
  journal={Acta oncologica},
  year={2008},
  volume={47 2},
  pages={
          176-86
        }
}
BACKGROUND Hand-foot skin reaction (HFSR) is a dose-limiting toxicity associated with sorafenib, an oral multi-kinase inhibitor with clinical activity against solid tumors. This study was conducted to determine the risk of developing HFSR among patients receiving sorafenib. PATIENTS AND METHODS Databases from Pubmed, Web of Science, and abstracts presented at the American Society of Clinical Oncology annual meetings from 2004 through July, 2007 were searched to identify relevant studies… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 1 time. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 77 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 52 REFERENCES

Bay43-9006 (sorafenib) can lead to improvement of bone lesions in metastatic androgenindependent prostate cancer despite rises in serum psa levels

  • CS WuSEP, P. M. Arlen
  • Prostate Cancer Symposium San Fransisco,
  • 2006
Highly Influential
4 Excerpts

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

  • K LSGhassan, R Sergio
  • J Clin Oncol
  • 2006
Highly Influential
6 Excerpts

CD: Bay 43-9006: Preclinical data

  • S Wilhelm
  • Curr Pharm Des ;8:2255
  • 2002
Highly Influential
4 Excerpts

A multicenter phase II trial of oral sorafenib in non - gist sarcomas ctep trial # 7060 . ASCO annual meeting Chicago , Illinois

  • KM D’AdamoDR, S Schuetze
  • J Clin Oncol
  • 2007

Similar Papers

Loading similar papers…